Clifford Chance, Maples and Calder JunHe advised SciClone Pharmaceuticals on its US$281 million initial public offering and listing on the main board of the Hong Kong…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
